PRESS RELEASE published on 01/08/2024 at 13:00, 10 months 14 days ago Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET. Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
PRESS RELEASE published on 12/20/2023 at 22:05, 11 months 1 day ago Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRESS RELEASE published on 12/15/2023 at 00:00, 11 months 7 days ago Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
PRESS RELEASE published on 12/14/2023 at 12:30, 11 months 8 days ago Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
PRESS RELEASE published on 12/12/2023 at 14:00, 11 months 10 days ago Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
PRESS RELEASE published on 12/07/2023 at 13:00, 11 months 15 days ago Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
PRESS RELEASE published on 11/14/2023 at 13:00, 1 year ago Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
PRESS RELEASE published on 11/08/2023 at 22:15, 1 year ago Moderna to Present at Upcoming Conferences in November 2023
PRESS RELEASE published on 11/08/2023 at 13:00, 1 year ago Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
PRESS RELEASE published on 11/07/2023 at 14:00, 1 year ago Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Published on 11/22/2024 at 14:45, 15 minutes ago Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 30 minutes ago Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Published on 11/22/2024 at 14:20, 40 minutes ago Plaintree Systems Inc. Announces Second Quarter Fiscal 2025 Results
Published on 11/22/2024 at 14:00, 1 hour ago Clear Start Tax Warns Taxpayers About Upcoming IRS Collection Changes in 2025
Published on 11/22/2024 at 14:46, 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/22/2024 at 14:44, 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Published on 11/22/2024 at 14:43, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc
Published on 11/22/2024 at 14:42, 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Published on 11/21/2024 at 06:58, 1 day 8 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 19 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 21 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 21 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
